Breaking News

Financial Report: ICON

By Kristin Brooks | February 20, 2014

Revenues up 15% in the quarter

4Q Revenues: $345 million (+15%)

4Q Earnings: $33.5 million (+62%)

FY Revenues: $1.34 billion (+20%)

FY Earnings: $102.8 million (+86%)

Comments: Operating income was $38.7 million or 11% of revenue in the quarter, and net business awards were $446 million representing a book to bill of 1.29. For the year operating income before non-recurring charges was $130.2 million or 10% of revenue, and net new business awards were $1.6 billion, representing a book to bill of 1.23. Backlog increased 12% for the year to $3.1 billion.
blog comments powered by Disqus
  • Flexible Manufacturing Strategies

    Kristin Brooks, Contract Pharma||April 4, 2016
    Michael Lehmann of Patheon discusses solutions for pharmaceutical forecasting errors

  • Platinum Press Facility Tour

    Platinum Press Facility Tour

    Kristin Brooks, Contract Pharma||March 23, 2016
    Opens doors to new, 47,000-sq.-ft. packaging facility in Oakland, NJ

  • Biopharma Packaging Equipment Close-up

    Biopharma Packaging Equipment Close-up

    Kristin Brooks, Contract Pharma||March 7, 2016
    Sieghard Schuchmann of OPTIMA discusses biopharma trends impacting packaging equipment, and the latest capabilities

  • Fit-For-Purpose Assay Development in Bioanalysis

    Fit-For-Purpose Assay Development in Bioanalysis

    Franklin Spriggs, Ligand Binding Assay Group Leader; Ashley Brant, Program Manager, AIT Bioscience||January 28, 2016
    The success of bioanalytical studies relies on the selection of the most suitable analytical method but the timeline of method development and types of analyses involved vary greatly.

  • Getting Real

    Michael Pollock, PPD||November 17, 2015
    Partnering for clinical and real-world evidence studies

  • Bringing Transparency and Collaboration to CRO Oversight

    Bringing Transparency and Collaboration to CRO Oversight

    Craig Morgan , goBalto Inc. ||November 17, 2015
    Relationships between sponsors and CROs are getting stronger